Manidipine
Catalog No.S2481
Molecular Weight(MW): 610.7
Manidipine is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
Biological Activity
| Description | Manidipine is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Manidipine, a Ca(2+)-channel blocker, at concentrations that lower elevated blood pressure, modulates the transcription rates of cytokine genes in the mesangial cells of humans that had been stimulated with platelet-derived growth factor BB isomer. [1] Manidipine inhibits the ET-1-induced [Ca2+]i increase by reducing both the transient and sustained Ca2+ increments in A7r5 cells and glomerular mesangial cells (MCs). Manidipine (10(-5) mol/L) potentiates ET-1-induced c-fos and c-jun expression in A7r5 cells. Manidipine is a potent inhibitor for ET-1-induced [Ca2+]i signaling and that Manidipine has multiple effects on ET-1-induced signaling, including potentiating the immediate-early gene response. [2] |
||
| In vivo | Manidipine reduces systolic blood pressure with a slight sympathetic reflex increase in heart rate, and increases plasma nitrite/nitrates in perfused rat heart from ischemia-reperfusion damage. Manidipine combined with Simvastatin reduces creatine kinase, lactate dehydrogenase and tumor necrosis factor-alpha, and enhancement of 6-keto-PGF(1alpha) during reperfusion. [3] Manidipine hydrochloride prevents isoproterenol-induced left ventricular hypertrophy and expression of mRNA of ANP, collagen types I and type III, and fibronectin in rats with isoproterenol-induced cardiac hypertrophy. [4] Manidipine HCl increases renal blood flow (RBF) by dilating the afferent arterioles and improves glomerular hypertension by dilating the efferent arterioles in hypertensive rats. [5] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 122 mg/mL (199.77 mM) |
|---|---|---|
| Ethanol | 3 mg/mL (4.91 mM) | |
| Water | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 610.7 |
|---|---|
| Formula | C35H38N4O6 |
| CAS No. | 89226-50-6 |
| Storage | powder |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00627952 | Completed | Hypertension | University of Erlangen-Nürnberg Medical School|Chiesi Farmaceutici S.p.A. | November 2007 | Phase 3 |
| NCT00157586 | Completed | Type 2 Diabetes | Mario Negri Institute for Pharmacological Research | February 2002 | Phase 3 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
